Fresenius Medical Care Amends Humacyte Stake Filing

TL;DR

Fresenius Medical Care updated its Humacyte stake filing - watch for changes.

AI Summary

Fresenius Medical Care Holdings Inc. /NY/ has amended its Schedule 13D filing regarding Humacyte, Inc. as of March 7, 2024. This amendment, designated as Amendment No. 2, indicates a change in the reporting person's beneficial ownership of Humacyte, Inc. stock. The filing does not specify the exact percentage or number of shares held but signals a potential shift in the major shareholder landscape.

Why It Matters

This filing indicates a change in beneficial ownership by a significant entity, which could signal shifts in investment strategy or influence over Humacyte, Inc.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D filings by major shareholders can precede significant corporate actions or market movements.

Key Players & Entities

• Fresenius Medical Care Holdings Inc /NY/ (company) — Reporting Person
• Humacyte, Inc. (company) — Subject Company
• Alpha Healthcare Acquisition Corp. (company) — Former Company Name of Humacyte, Inc.

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securitie

Filing Documents

• tm248114d1_sc13da.htm (SC 13D/A) — 74KB
• 0001104659-24-031844.txt ( ) — 76KB

of the Schedule 13D is hereby amended as set forth below

Item 2 of the Schedule 13D is hereby amended as set forth below: On January 1, 2024, Mr. Craig Cordola assumed office as a member of the Management Board of FME AG and CEO of FME AG’s Care Delivery segment. As previously disclosed in this Schedule 13D, on November 30, 2023, Fresenius Medical Care successfully completed its change of legal form from a German partnership limited by shares into a German stock corporation. The change of legal form included the formation of a new Supervisory Board, initially consisting of six shareholder representatives. Upon the effective date of the Conversion, FME AG became a supervisory board with parity co-determination (i.e., rules requiring employee participation in the supervisory boards of certain German enterprises on a basis of parity). Effective January 26, 2024, the competent court approved FME AG's application for the judicial appointment of six employee representatives to FME AG’s Supervisory Board. With the appointment of the six employee representatives, the FME AG Supervisory Board now has full and equal representation. The judicial appointment of the six employee representatives will remain effective until completion of the election of employee representatives by the FME AG workforce located in Germany. Schedule I to this Schedule 13D, setting forth information with respect to the directors and officers of FMCH, the members of the Supervisory Board of FME AG and the members of the Management Board of FME AG, is hereby amended and restated in its entirety as set forth in Schedule I to this Schedule 13D (Amendment No. 2). Item 5. Interest in Securities of the Issuer

of the Schedule 13D is hereby amended

Item 5 of the Schedule 13D is hereby amended by the addition of the following information: On the date of this Schedule 13D (Amendment No. 2), the Filing Persons are the beneficial owners of 18,312,735 shares of the Issuer’s Common Stock. On March 5, 2024, the Issuer completed a public offering of 15,410,000 shares of its Common Stock. The increase in the total outstanding shares of the Issuer’s Common Stock resulting from the public offering reduced the Filing Persons’ beneficial ownership of the Issuer’s Common Stock from 17.7% of such outstanding shares to 15.4% of such outstanding shares. This change in the Filing Persons’ percentage beneficial ownership resulted solely from the increase in the number of outstanding shares of Common Stock in the Issuer’s public offering. Neither of the Filing Persons has disposed of or acquired any shares of the Issuer’s Common Stock subsequent to the filing of the initial Schedule 13D in September 2021. 4 Signature After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. Dated: March 7, 2024 FRESENIUS MEDICAL CARE HOLDINGS, INC. By: /s/ Bryan Mello Name: Bryan Mello Title: Vice President and Assistant Treasurer FRESENIUS MEDICAL CARE AG By: /s/ Franklin W. Maddox Name: Franklin W. Maddux Title: Member of Management Board and Global Chief Medical Officer By: /s/ Peter Hennke Name: Peter Hennke Title: Authorized Signatory ( Prokurist ) 5 SCHEDULE I The officers and members of the board of directors FMCH, the members of the Management Board of FME AG, and the members of the Supervisory Board of FME AG, their respective present principal occupations or employment, and their respective business addresses are set forth below. Each of the directors of FMCH is also a member of the FME AG Management Boa

View Full Filing

View this SC 13D/A filing on SEC EDGAR